Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Andreas Pinter,Kilian Eyerich,Antonio Costanzo,Alyssa Garrelts,Christopher Schuster,Can Mert,Anastasia Lampropoulou,Konstantinos Fotiou,Julia-Tatjana Maul,Kim A. Papp
DOI: https://doi.org/10.1080/09546634.2024.2350227
2024-05-28
Journal of Dermatological Treatment
Abstract:Purpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoHO), is to provide evidence if early intervention with biologics is associated with better treatment outcomes and if there is any difference among drug classes or individual biologics.
dermatology
What problem does this paper attempt to address?